Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075618 | 0.79 | HTR2C (0.38) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL1831339 | 0.78 | GLS (0.50) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL30264842 | 0.78 | HSP90AA1 (0.49) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL7021352 | 0.78 | GLS (0.53) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL16942777 | 0.78 | HSD17B2 (0.53) | GLSHTR2CSLC6A4RIPK1 | |
| SCHEMBL14426297 | 0.78 | HSP90AA1 (0.49) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL2228851 | 0.77 | HSD11B1 (0.51) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL2176070 | 0.77 | RIPK1 (0.63) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL27440203 | 0.77 | GLS (0.49) | GLSHTR2CSLC6A4AOC3RIPK1 | |
| SCHEMBL4742321 | 0.77 | CYP1A2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| EP-1893578-A2 | NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006129237-A2 | NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | GLS 7/4885HTR2C 2669/4885SLC6A4 2410/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | GLS 4/4885HTR2C 1693/4885SLC6A4 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.